Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease
- PMID: 27134484
- PMCID: PMC4835588
- DOI: 10.3346/jkms.2016.31.5.649
Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease
Abstract
Nontuberculous mycobacteria (NTM) are ubiquitous organisms; their isolation from clinical specimens does not always indicate clinical disease. The incidence of NTM lung diseases has been increasing worldwide. Although the geographic diversity of NTM species is well known, Mycobacterium avium complex (MAC), M. abscessus complex (MABC), and M. kansasii are the most commonly encountered and important etiologic organisms. Two distinct types of NTM lung diseases have been reported, namely fibrocavitary and nodular bronchiectatic forms. For laboratory diagnosis of NTM lung diseases, both liquid and solid media cultures and species-level identification are strongly recommended to enhance growth detection and determine the clinical relevance of isolates. Treatment for NTM lung diseases consists of a multidrug regimen and a long course of therapy, lasting more than 12 months after negative sputum conversion. For MAC lung disease, several new macrolide-based regimens are now recommended. For nodular bronchiectatic forms of MAC lung diseases, an intermittent three-time-weekly regimen produces outcomes similar to those of daily therapy. Treatment of MABC lung disease is very difficult, requiring long-term use of parenteral agents in combination with new macrolides. Treatment outcomes are much better for M. massiliense lung disease than for M. abscessus lung disease. Thus, precise identification of species in MABC infection is needed for the prediction of antibiotic response. Likewise, increased efforts to improve treatment outcomes and develop new agents for NTM lung disease are needed.
Keywords: Mycobacterium abscessus; Mycobacterium avium Complex; Mycobacterium kansasii; Nontuberculous Mycobacteria.
Conflict of interest statement
Figures

Similar articles
-
Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01105-18. doi: 10.1128/AAC.01105-18. Print 2018 Oct. Antimicrob Agents Chemother. 2018. PMID: 30104265 Free PMC article.
-
Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.Respir Med. 2019 May;151:1-7. doi: 10.1016/j.rmed.2019.03.014. Epub 2019 Mar 26. Respir Med. 2019. PMID: 31047103
-
Changing Epidemiology of Nontuberculous Mycobacterial Lung Diseases in a Tertiary Referral Hospital in Korea between 2001 and 2015.J Korean Med Sci. 2018 Feb 19;33(8):e65. doi: 10.3346/jkms.2018.33.e65. J Korean Med Sci. 2018. PMID: 29441757 Free PMC article.
-
[Nontuberculous mycobacterial infections of the lung].Ther Umsch. 2011 Jul;68(7):402-6. doi: 10.1024/0040-5930/a000184. Ther Umsch. 2011. PMID: 21728159 Review. German.
-
Antibiotic treatment for nontuberculous mycobacterial lung disease.Expert Rev Respir Med. 2016;10(5):557-68. doi: 10.1586/17476348.2016.1165611. Epub 2016 Mar 30. Expert Rev Respir Med. 2016. PMID: 26967761 Review.
Cited by
-
Genetic Evolution of Mycobacterium abscessus Conferring Clarithromycin Resistance during Long-Term Antibiotic Therapy.Can Respir J. 2020 Mar 28;2020:7623828. doi: 10.1155/2020/7623828. eCollection 2020. Can Respir J. 2020. PMID: 32300380 Free PMC article.
-
PARK2 as a susceptibility factor for nontuberculous mycobacterial pulmonary disease.Respir Res. 2024 Aug 14;25(1):310. doi: 10.1186/s12931-024-02946-4. Respir Res. 2024. PMID: 39143598 Free PMC article.
-
Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio According to the Radiologic Severity of Mycobacterium avium Complex Pulmonary Disease.J Korean Med Sci. 2022 Oct 17;37(40):e292. doi: 10.3346/jkms.2022.37.e292. J Korean Med Sci. 2022. PMID: 36254530 Free PMC article.
-
Mycobacterium xenopi related spine infections: A case report and systematic literature review.One Health. 2023 Feb 11;16:100502. doi: 10.1016/j.onehlt.2023.100502. eCollection 2023 Jun. One Health. 2023. PMID: 36817979 Free PMC article.
-
In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00665-19. doi: 10.1128/AAC.00665-19. Print 2019 Aug. Antimicrob Agents Chemother. 2019. PMID: 31182533 Free PMC article.
References
-
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. - PubMed
-
- Falkinham JO., 3rd Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015;36:35–41. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical